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Abstract: With the aim to obtain new antimicrobials against important pathogens such as
Staphylococcus aureus and Pseudomonas aeruginosa, we focused on antimicrobial peptides (AMPs)
from Echinoderms. An example of such peptides is Paracentrin 1 (SP1), a chemically synthesised
peptide fragment of a sea urchin thymosin. In the present paper, we report on the biological
activity of a Paracentrin 1 derivative obtained by recombination. The recombinant paracentrin RP1,
in comparison to the synthetic SP1, is 22 amino acids longer and it was considerably more active
against the planktonic forms of S. aureus ATCC 25923 and P. aeruginosa ATCC 15442 at concentrations
of 50 µg/mL. Moreover, it was able to inhibit biofilm formation of staphylococcal and P. aeruginosa
strains at concentrations equal to 5.0 and 10.7 µg/mL, respectively. Molecular dynamics (MD)
simulations allowed to rationalise the results of the experimental investigations, providing atomistic
insights on the binding of RP1 toward models of mammalian and bacterial cell membranes. Overall,
the results obtained point out that RP1 shows a remarkable preference for bacterial membranes,
in excellent agreement with the antibacterial activity, highlighting the promising potential of using
the tested peptide as a template for the development of novel antimicrobial agents.
Keywords: AMP (antimicrobial peptides); biofilm; Staphylococcus aureus; Pseudomonas aeruginosa;
thymosin; Paracentrotus lividus; molecular dynamics
1. Introduction
The onset of multidrug-resistant Gram-positive and Gram-negative bacterial strains has made
most of the current antibiotics less effective, making the research of novel therapeutic strategies
against pathogens an urgent topical issue [1]. Furthermore, even if conventional antibiotics can be
effective against free living bacterial cells, there are few agents that effectively target the pathogens in
a biofilm form. The biofilm is a three-dimensional microbial community that grows on both biological
and abiotic surfaces. Opportunistic pathogens, such as staphylococcal strains and Pseudomonas
aeruginosa, show a great ability to produce biofilms that prevent infected wounds from healing,
rendering the treatment extremely challenging [2]. Unfortunately, the introduction in therapy of new
molecules effective against P. aeruginosa and staphylococcal strains is extremely slow. Additionally,
the treatment of biofilm-associated infections is complicated because microbial biofilms show a
multifactorial antibiotic resistance linked to their growth as a community [3]. The discovery of
anti-infective agents active against both forms of growth, planktonic and biofilm, represents a
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fundamental goal for an effective control of infections [4,5]. This has stimulated the research for
antibiotic alternative strategies in the struggle against pathogens. Many antimicrobial peptides (AMPs)
show a high specificity for prokaryotes and a low toxicity for eukaryotic cells and, due to their mode
of action, the development of resistance is considered less probable. It is well known that the marine
invertebrates are a good source of AMPs [6], and a variety of peptides with antimicrobial properties
have been isolated from the Echinodermata phylum [7,8]. We recently found and described three
peptides, fragments of a β-thymosin of Paracentrotus lividus, the sea urchin from Mediterranean Sea [9].
In particular, we focused on the smallest 11 amino acid peptide (9–19), whose molecular weight was
1251.7, that we called Paracentrin 1 (SP1, EVASFDKSKLK). We demonstrated a broad range of activity
against planktonic and biofilm forms of representative pathogens, like staphylococcal strains and
P. aeruginosa, but we found Minimum Inhibitory Concentration (IC)values in the order of mg/mL [10].
Subsequently, we compared the amino acid sequence of SP1 with the corresponding fragment 9–19
(EIEKFDKSKLK) of human thymosin β4 (Tβ4). We observed, using molecular dynamics (MD)
simulations, that the conformations adopted by these two peptides in a physiological environment
are very similar and, then, their interaction with model membranes and biological activities in vitro,
with MIC values ranging from 12.5 to 6.2 mg/mL [11].
In order to improve the biological activity of SP1 we obtained, by recombination,
the recombinant Paracentrin 1 (RP1), being 22 amino acids longer in the amino terminal region
in comparison with SP1 (MSGSHHHHHHGSSGENLYFQSLEVASFDKSKLK, with SP1 portion
highlighted in bold). In the present study, we compared the structure and dynamics of RP1
with the chemically synthesised SP1. The interaction of RP1 with two membrane models in
silico, and the antibacterial and anti-biofilm activity in vitro, were also evaluated. Two lipid
bilayers were used in this study: POPC (1-palmitoyl-2-oleoylphosphatidylcholine) and POPC: POPG
(1-palmitoyl-2-oleoylphosphatidylglycerol) (2:1). These models were chosen in order to mimic the
mammalian and bacterial cell membrane, respectively. Additionally, the antibacterial and antibiofilm
activities against a staphylococcal reference strain S. aureus ATCC 25923 and P. aeruginosa ATCC 15442
are reported.
2. Results
2.1. Antibacterial Activity of RP1
RP1 was tested in vitro at concentrations ranging from 100 to 0.75 µg/mL against two reference
bacterial strains, S. aureus ATCC 25923, and P. aeruginosa ATCC 15442. The antibacterial activity,
expressed as MICs (minimum inhibitory concentrations), is reported in Table 1. RP1 is able to interfere
with microbial growth of all tested strains at MIC concentrations of 50 µg/mL. It is interesting
to highlight that RP1 resulted in being 250 times more active against S. aureus ATCC 25923 and
P. aeruginosa ATCC1 15442 than SP1 (MIC of 12.5 mg/mL against abovementioned bacterial strains) [10],
and comparable with the MIC of LL-37 a human AMP derived from cathelicidin hCAP-18.
Table 1. Antibacterial activity, in vitro, of RP1 and LL37.
Reference Strains
MIC (µg/mL)
RP1 LL-37
S. aureus ATCC 25923 50 50
P. aeruginosa ATCC 15442 50 50
2.2. Interference with Biofilm Formation
The ability of RP1 to inhibit biofilm formation of staphylococcal reference strains, as S. aureus
ATCC 25923 and P. aeruginosa ATCC 15442, was tested at concentrations lower than the MIC observed
against planktonic form. The values of biofilm inhibition concentration, BIC50, in interfering with
biofilm formation, were found to be of 5.0 µg/mL against S. aureus ATCC 25923 and 10.7 µg/mL
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against P. aeruginosa ATCC 15442; see Table 2. Remarkably also, in this case, we observed a considerable
improvement of the activity, being 1000 times more active as biofilm inhibitor than SP1 (whose BIC50
were 0.3 and 1.5 mg/mL against the abovementioned pathogens). LL-37, tested for comparative
purposes, showed a BIC50 of 1.6 µg/mL or 12.9 µg/mL, respectively, against the staphylococcal strains
or P. aeruginosa ATCC 15442.
Table 2. Inhibition of biofilm formation.
Reference Strains
BIC (µg/mL)
RP1 LL-37
S. aureus ATCC 25923 5.0 ± 0.3 1.6 ± 0.04
P. aeruginosa ATCC 15442 10.7 ± 0.7 11.9 ± 0.9
2.3. Molecular Dynamics of RP1
The novel recombinant peptide investigated in this work, RP1, has the following amino acid
sequence: MSGSHHHHHHGSSGENLYFQSLEVASFDKSKK. Due to the longer sequence of RP1
in comparison with the previously investigated SP1 [10], we have generated a starting peptide
conformation using the PEP-FOLD webserver [12]. A 500 ns MD simulation was performed on the
lowest energy model, in order to relax the structure in a physiological environment. This conformation
proved to be stable during the whole simulation and the most representative structure was extracted
using a cluster analysis. According to the secondary structural motifs, we can ideally divide RP1 in
three sections (see Figure 1). The first portion (RP1-1), ranging from Met1 to Gly11 (Figure 1a blue),
is composed mainly by histidine residues, and it remains mostly unstructured at the end of the MD
simulation. The second part represents the main peptide core (RP1-2), and it is formed by an α-helix
made by residues Ser12–Leu22 (Figure 1a, red). The third portion of RP1 (RP1-3), from Glu23 to Lys33,
corresponds to the SP1 peptide having a partially unfolded structure, stabilised by intramolecular
hydrogen bonds with the main helical core (Figure 1a, yellow). The most representative RP1
conformation is constituted by an asymmetric distribution of charges between the less polar α-helical
core RP1-2 and the two more polar RP1-1 and RP1-3 sequences (see Figure 1b). RP1-3 possesses the
highest number of charged residues (one Glu, one Asp, and three Lys) while the remaining part is still
slightly polar, and has only one charged residue (Glu15).
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the membranes. In particular, 300 ns MD simulations were performed for both membrane models
using the “minimum bias” method, [13] in which the lipids self-organise spontaneously in ordered
bilayers in reasonable time-scales, i.e., less than 100 ns. Remarkably, while RP1 binds only superficially
to the mammalian POPC model, it suddenly inserts and remains deeply buried inside the bacterial
POPC/POPG model, as shown in Figure 2, until the end of the MD simulation. The position of RP1
and the evolution of the forming bilayer are shown using density profiles taken at different simulation
times (Figure 3). At the beginning of the POPC-RP1 MD simulation, water and lipids are almost
homogeneously mixed and, after 100 ns, the lipid bilayer is formed. The charged SP1 portion of the
peptide, RP1-3, preferentially interacts with the POPC polar heads until the end of the simulation,
while the remaining RP1 residues are still solvated (Figure 3c top). Remarkably, the POPC/POPG-RP1
simulation shows a different behaviour. After 140 ns, two almost symmetrical leaflets are formed
showing similar lipid composition (Figure 3b,c bottom). RP1 is localised almost in the centre of the
membrane, deeply affecting the shape of the bilayer and remaining stably bound until the end of
the simulation. The same RP1 interaction with the POPC/POPG membrane model was confirmed
in another 300 ns replica. Moreover, while the bilayer is formed, water is not completely excluded
from the hydrophobic centre, suggesting the presence of a membrane defect induced by RP1. In order
to check the stability of the defect, two annealing cycles (as described in the Materials and Methods
section), each followed by 100 ns of MD simulation, were performed, for a total simulation time of
about 500 ns. The defect formed by the presence of RP1 was not healed after both annealing steps
(see Figure 4a), suggesting that this is not an artefact introduced by the simulation, but real membrane
damage induced by the presence of RP1 inside the bacterial model. This remarkable selectivity seems
to be driven by the electrostatic interactions among the positively charged Lys residues of RP1-3 with
the negatively charged POPG heads (Figure 4b), as clearly shown by the radial distribution function,
g(r), between Lys residues and the phosphorous atoms of the POPC and POPG lipids (Figure 4c).
Hence, RP1-3 acts as an anchor, while the first two, more hydrophobic RP1 portions, RP1-1 and RP1-2,
remain deeply buried inside the newly formed membrane.
Mar. Drugs 2018, 16, x FOR PEER REVIEW  4 of 10 
 
with the membranes. In par icular, 00 ns MD simulat ons were performed for b th membrane 
models using the “minimum bias” method, [13] i  which the lipids self-organise sp taneously in 
ordered bil yers in reasonable time-scales, i.e., l ss than 100 ns. Remarkably, while RP1 binds only 
superficially to the mammalian POPC model, it suddenly inserts and remains deeply buried inside 
the bacterial POPC/POPG model, as shown in Figure 2, until the end of the MD simulation. The 
position of RP1 and the evolution of the forming bilayer are shown using density profiles taken at 
different simulation times (Figure 3). At the beginning of the POPC-RP1 MD simulation, water and 
lipids are almost homogeneously mixed and, after 100 ns, the lipid bilayer is formed. The charged 
SP1 portion of the peptide, RP1-3, preferentially interacts with the POPC polar heads until the end of 
the simulation, while the remaining RP1 residues are still solvated (Figure 3c top). Remarkably, the 
POPC/POPG-RP1 simulation shows a different behaviour. After 140 ns, two almost symmetrical 
leaflets are formed showing similar lipid composition (Figure 3b,c bottom). RP1 is localised almost 
in the centre of the membrane, deeply affecting the shape of the bilayer and remaining stably bound 
until the end of the simulation. The same RP1 interaction with the POPC/POPG membrane model 
was confirmed in another 300 ns replica. Moreover, while the bilayer is formed, water is not 
completely excluded from the hydrophobic centre, suggesting the presence of a membrane defect 
induced by RP1. In rder to check the stability of the d fect, two annealing cycles (as described in e 
Materials and Methods sectio ), each followed by 100 ns of MD simulation, were performed, for a 
to al simulation tim  of about 500 ns. The defect formed by the presence of RP1 was not healed after 
both annealing steps (see Figure 4a), suggesting that this is not an artef ct introduced by the 
simulation, but real membrane damage induced by the presence of RP1 inside the bacterial model. 
This remarkable selectivity seems to be driven by the electrostatic interactions among the positively 
charged Lys residues of RP1-3 with the negatively charged POPG heads (Figure 4b), as clearly 
shown by the radial distribution function, g(r), between Lys residues and the phosphorous atoms of 
the POPC and POPG lipids (Figure 4c). Hence, RP1-3 acts as an anchor, while the first two, more 
hydrophobic RP1 portions, RP1-1 and RP1-2, remain deeply buried inside the newly formed 
membrane. 
 
Figure 2. The selective interaction between RP1 and the mammalian and bacterial membrane 
models. Two representative snapshots showing the interaction of RP1 with (a) the POPC and (b) the 
POPC (blue)/POPG (red) membrane models. RP1 and phosphorous atoms are shown in van der 
Waals representation. 
Figure 2. The selective interaction between RP1 and the mammalian and bacterial membrane
models. Two representative snapshots showing the interaction of RP1 with (a) the POPC and (b)
the POPC (blue)/POPG (red) membrane models. RP1 and phosphorous atoms are shown in van der
Waals representation.
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3. Discussion
In this study, we prepared a recombinant new peptide, RP1, deriving from SP1, an antibacterial
peptide present in P. lividus coelomocytes [10]. The structure of RP1 is significantly different from
the chemically synthesised SP1. In fact, the addition of the RP1-1 and RP1-2 moieties to the SP1
original structure (represented here by the RP1-3 portion, see Figure 1) enriches the novel recombinant
peptide with important structural features shared by common AMPs: (i) an α-helix structural core;
(ii) a net positive charge that favours electrostatic attractions towards the negatively charged microbial
membranes; and (iii) an amphipathic organisation, that confers to RP1 a stronger bilayer interaction,
especially with bacterial membrane models. As a consequence, RP1 has shown a remarkable
improvement of the antimicrobial and antibiofilm activity in comparison to SP1 (which resulted
to be 250 and 1000 times higher, respectively) and an activity in vitro against tested pathogens similar
to human host defence peptide LL-37. The amphipathic α-helical antimicrobial peptides are produced
by organisms that are evolutionarily quite distant, ranging from protostomes such as insects [14–16] to
deuterostomes such as echinoderm [17], tunicates [18], and vertebrates [19–21]. They have evolved
to function in many different environments, such as the haemolymph of insects [22], amphibian skin
secretions [23–25], gastric mucosa and intestinal epithelia, mammalian phagocytic vacuoles, wound
and blister fluids, and epithelia [26–28]. In this work, we have performed MD simulations with
the aim to provide the molecular mechanism by which the title peptide exerts its biological activity.
Remarkably, our simulations have highlighted a preferential interaction of RP1 with the bacterial
membrane model, due to the electrostatic attraction among the negatively charged POPG lipids and
the positively charged Lys residues of RP1-3, being in excellent agreement with the antibacterial and
the antibiofilm activity experimentally observed. Furthermore, such peptides could, in principle,
also hit metabolically low active bacterial cells, intrinsically resistant to conventional antibiotics.
4. Materials and Methods
4.1. Paracentrin 1 Gene Cloning
The nucleotide sequence of the sea urchin Paracentrin 1 peptide was cloned
in a pFastBac™-Dual vector (Life Technologies Italia, Monza, Italy)) using the
Bac-to-Bac® N-His TOPO® cloning kit (Life technologies). In particular, two partially
complementary oligonucleotides were synthesised by BMR Genomics Custom Primer
Service, Padova, Italy) (For: 5’-GAAGTTGCATCTTTCGACAAGTCGAAACT-3’, Rev:
5’-TTACTTAAGTTTCGACTTGTCGAAAGATG-3’) and used as primer and template in a PCR reaction
with the Platinum Pfx DNA Polymerase (Life Technologies) (25 cycles: 94 ◦C for 15 s, 52 ◦C for 30 s,
68 ◦C for 45 s, and a final extension at 68◦ C for 10 min.) The oligonucleotides were designed in order
to include the Paracentrin 1 gene sequence and a stop codon at the end of the gene.
4.2. Peptide Expression
Recombinant bacmid was generated in DH10Bac™ cells using the Bac-to-Bac® N-His TOPO®
(Life technologies) and extracted using Ni-NTA Purification system (Invitrogen). In particular,
Spodoptera frugiperda (Sf9) cells (Life Technologies) were cultured in suspension flasks on a rotating
platform (110 RPM at 26 ◦C) using an incubator shaker and Sf-900 II media following the supplier’s
manual. Recombinant progeny 1 baculovirus (RPB1) was produced in monolayer cultures by
transfecting 5 mL Sf9 cells (1.0 × 106 cells/mL grown in 25 cm2 flasks), and was harvested after
6 days, aliquoted, and stored at −80 ◦C. Recombinant progeny 2 baculovirus (RPB2) virus was
generated by infecting Sf9 suspension cultures (1.5 × 106 cells/mL) with RPB1 virus (400 µL/100 mL
cells). The supernatant from this culture (RPB2) was harvested 72 h post-infection, and 3 mL was used
to infect 600 mL of Sf9 suspension culture (1.5 × 106 cells/mL), thus generating a recombinant progeny
3 baculovirus (RPB3) virus 72 h post-infection. The baculovirus present in this culture (RPB3) was
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quantified using the kit BacPak qPCR titration kit (Clontech Takara Bio USA, Inc.) and 2 L of Sf9 cells
(1.0 × 106 cells/mL) were infected at a MOI (multiplicity of infection) of 5 for protein production.
For His-tagged protein production, cells were grown in suspension for 48 h, and the cell pellets
was used for protein extraction according to the Ni-NTA Purification system (Invitrogen) protocol.
An aliquot of the eluate was loaded on a Sepharose 100 column, pre-equilibrated in 10 mM sodium
phosphate buffer.
MSGSHHHHHHGSSGENLYFQSLEVASFDKSKLK
4.3. Microbial Strains
Staphylococcus aureus ATCC 25923 and Pseudomonas aeruginosa ATCC 15442, the reference strains in
official tests for antibacterial evaluation in vitro (UNI EN European Standard), were used in this study.
4.4. Minimum Inhibitory Concentrations (MICs)
MICs were determined by a previously described micromethod [10]. Briefly, a series of solutions
were prepared with a range of concentrations from 100 to 0.75 µg/mL (obtained by two-fold serial
dilution). The serial dilutions were made in tryptic soy broth (TSB) (VWR International, Leuven) in
a 96-wells plate, starting from a stock solution of 1 mg/mL in NaCl 0.9% w/v. To each well, 10 µL
of a bacterial suspension from a 24 h culture containing ~106 cfu/mL was added. The plate was
incubated at 37 ◦C for 24 h; after this time, the MICs were determined by a microplate reader (Glomax
Multidetection System TM297 Promega, Milano Italy) as the lowest concentration of compound
whose OD, read at 570 nm, was comparable with the negative control wells (broth only, without
inoculum). We also tested the known active peptide, LL-37, for comparative and quality control
purposes. Each assay was performed in triplicate and repeated at least twice.
4.5. Evaluation of Biofilm Formation and Biofilm Prevention Assay
The bacterial reference strains were tested for their ability to form biofilms. The evaluation assay
was previously described elsewhere [29]. Briefly, S. aureus ATCC 25923 and P. aeruginosa ATCC 15442
were grown, diluted, and wells were washed as described by [30]. The plates were air-dried at 37 ◦C,
and each well was filled with 100 µL of TSB supplemented with several concentrations, ranging from
12.5 to 0.2 µg/mL, of RP1 or LL-37 at sub-MIC concentrations, except in the case of positive controls.
The plates were incubated at 37 ◦C for 24 h; after this incubation time, the medium was removed,
the plates were air-dried and, then, a crystal violet solution (0.1%) was added to each well, followed
by incubation for 15–20 min. The plate was then washed three times with water, and the crystal violet
was dissolved in 150–200 µL of ethanol by pipetting up and down. The plate was read at 570 nm
using a microplate reader (Glomax Multidetection System Promega). Biofilm inhibitory concentration
(BIC50), that is, the concentration at which the percentage of inhibition of biofilm formation (see below)
is equal to 50% were obtained by comparing the optical densities (ODs) of control wells with that of
the sample wells, and the value was calculated by using a linear regression graph in Excel. Each assay
was performed in triplicate and repeated at least twice.
The percentage of inhibition was calculated through the formula
% of inhibition = ((OD growth control − OD sample)/OD growth control) × 100 (1)
4.6. Molecular Dynamics Simulations
The PEP-FOLD webserver [12] was used to obtain a folded structure of RP1 and the lowest energy
model was taken as a starting point for subsequent simulations. The stability of this conformation
in physiological conditions was investigated, in silico, by molecular dynamics (MD) simulations,
following reported procedures [31]. The interaction of RP1 with two membrane models was studied
using the “minimum-bias” method, [13] in which disordered lipids self-organise spontaneously in the
presence of AMPs. The software packmol [32] was used to generate the starting configuration. Peptides
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were placed in the centre of a cubic box having sides of 12 Å. Into the box were added 128 POPC for
the mammalian model, 86 POPC and 42 POPG for the bacterial model, as well as 7500 water molecules.
The Amber99SB-ILDN force field [33], implemented in the GROMACS 4.6.5 software package [34],
was used in combination with the Slipids (Stockholm lipids) force field for lipids [35,36]. Pressure
coupling was applied anisotropically, using a Parrinello–Rahman barostat with a reference value of
1 bar [37]. First, a short 100 ps equilibration was performed in order to achieve the target density of
the system, followed by 300 ns production runs. MD simulations were replicated. In the case of the
POPC/POPG, model MD simulations were followed by annealing cycles in which the temperature was
increased from 300 K to 375 K in 2 ns and, again, decreased to 300 K in 50 ps, as previously reported
in the literature, in order to heal membrane defects [38]. Afterwards, another 100 ns simulation was
performed at 300 K. Figures and plots were obtained by the VMD software [39]. Density profiles were
calculated with the GROMACS tool g_density. Clustering analysis was performed by g_cluster tool,
also included in the GROMACS package.
5. Conclusions
Considering the recent dramatic increment of multidrug-resistant microbial pathogens and the
urgent need for novel therapeutic strategies, our results lay the foundation for the development of
novel AMPs using RP1 scaffold as a potential and effective template.
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